Valuation : Forte Biosciences, Inc.

Market Cap 193.91Cr 166.45Cr 155.83Cr 142.69Cr 268.81Cr 19TCr 269.57Cr 1.85TCr 721.35Cr 9.33TCr 728.02Cr 712.3Cr 31TCr P/E 2026 *
-19.4x
P/E 2027 * -18.9x
Enterprise Value 193.91Cr 166.45Cr 155.83Cr 142.69Cr 268.81Cr 19TCr 269.57Cr 1.85TCr 721.35Cr 9.33TCr 728.02Cr 712.3Cr 31TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Forte Biosciences, Inc.

1 day+0.03%
1 week+0.12%
Current month+0.51%
1 month+40.54%
3 months+250.91%
6 months+163.12%
Current year+182.32%
1 week 76.89
Extreme 76.89
77
1 month 76.5
Extreme 76.5
77.2
Current year 15.51
Extreme 15.51
77.2
1 year 10.11
Extreme 10.11
77.2
3 years 4.11
Extreme 4.11
77.2
5 years 4.11
Extreme 4.11
786.75
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

Chief Financial Officer

884 0.0043%
01/07/26 Fiscal year

Chief Executive Officer

2,598 0.0127%
29/05/26 Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.12%+583.75%+266.62% 193.91Cr
+3.31%-3.70%+61.03%+103.64% 7.04TCr
+1.09%+3.40%+51.59%+93.39% 6.54TCr
-1.03%+0.46%+8.14%-7.69% 2.83TCr
-0.49%+5.43%+54.81%+13.87% 2.66TCr
-2.41%-2.95%-9.77%+461.47% 2.72TCr
+0.37%+0.70%+37.37%-15.78% 2.01TCr
+1.02%+6.43%+269.42%+420.34% 2.06TCr
+0.77%+0.19%+8.01%+520.34% 1.59TCr
-1.50%+2.92%+43.50%+149.14% 1.39TCr
Average +0.17%+1.05%+110.79%+200.53% 2.9TCr
Weighted average by Cap. +0.80%+0.72%+59.47%+156.04%

Financials

2026 *2027 *
Net sales - -
Net income -9.11Cr -7.82Cr -7.32Cr -6.7Cr -13Cr -870.18Cr -13Cr -87Cr -34Cr -438.56Cr -34Cr -33Cr -1.45TCr -11Cr -9.22Cr -8.63Cr -7.9Cr -15Cr -1.03TCr -15Cr -102.21Cr -40Cr -516.99Cr -40Cr -39Cr -1.71TCr
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
23
Date Price Change Volume
26/26/26 $76.99 +0.03% 14,00,110
25/26/25 $76.97 +0.03% 12,35,752
24/26/24 $76.95 +0.04% 12,55,679
21/26/21 $76.92 +0.04% 20,12,128
20/26/20 $76.89 -0.01% 31,96,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
76.99USD
Average target price
73.80USD
Spread / Average Target
-4.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock